CLEVELAND and HONOLULU, Sept. 29, 2015 /PRNewswire/ -- GenomOncology and Hawai'i Pathologists' Laboratory (HPL) today announced that HPL has launched the state's first tumor DNA profiling tests based on next generation sequencing (NGS). HPL selected the GenomOncology team and its GO Precision Medicine Portfolio™ to drive their test validation, analysis, interpretation, and reporting processes.
HPL has launched its NGS testing services with an initial focus on acute myeloid leukemia and solid tumors such as lung and colon cancer. "Offering cutting-edge tumor profiling tests to our patients at The Queen's Medical Center is an imperative in today's practice of oncology," said Christopher Lum, M.D., Pathologist at HPL. "We selected GenomOncology as a partner in implementing this new testing technology. Their tools simplify a highly complex procedure from test validation to reporting, while enabling us to be compliant, effectively scale, and offer the latest tests to our oncologists and their patients."
The GO Precision Medicine Portfolio is a full suite of tools designed to help healthcare institutions implement, perform, and maximize the benefits of precision medicine. The tools are installed behind the institution's firewall and are configured to each laboratory's specific needs. HPL employed the GO Validation Toolkit™ module to plan the assay validation experiments and to prepare documents needed under CAP / CLIA laboratory guidelines. With validation complete, patient testing is managed by the GO Clinical Workbench™, which provides a step-by-step workflow for the laboratory to perform quality control, evaluate all detected variants, and dynamically generate and sign out clinical reports based on validated rules.
"Here in Hawaii, we have a distinctive patient population," continued Dr. Lum. "With the GO Clinical Workbench we can accumulate critical knowledge about genetic variants that are clinically relevant or benign across diverse ancestry, such as Japanese, European, and Polynesian. Combining that local expertise with the well curated data already built into GenomOncology's systems, our lab can continuously learn about these populations, and ultimately, offer better care."
About Hawai'i Pathologists' Laboratory
Hawai'i Pathologists' Laboratory (HPL) is one of the leading providers of Anatomic Pathology and Cytopathology services in Hawai'i and the Pacific basin. HPL headquarters is located at The Queen's Medical Center, Honolulu, Hawai'i. HPL's core area of expertise lies in the diagnostic interpretation of a wide range of specimens including Bone Marrows, Surgical Resections, Biopsies and Cytologic Preparations.
GenomOncology is a healthcare technology company enabling precision medicine by transforming genomic data into actionable information. The GO Precision Medicine Portfolio™ is trusted by molecular pathologists and medical geneticists for streamlined development and production of knowledge- and guideline-driven cancer and hereditary disease tests. GenomOncology's technology allows multiple modes of genetic analysis to fuel integrated clinical decision support and research built on accumulating experience. Learn more at www.genomoncology.com.
For more information regarding this announcement, please contact:
Ben Salisbury, Vice President, New Products and Marketing